Medical Therapeutics

Zenith Therapeutics

Brief Description

Zenith Therapeutics is redefining drug discovery through a new approach to protein degradation, making hard-to-drug targets of high therapeutic value accessible to drug discovery.

Inventors

Julia Sabine Schaletzky, Michael Rape, Edward Eric Wehri, Andrew G. Manford, Srivdya Chandrasekhar, Daniel K. Nomura, Nathaniel J. Henning

Timeline 2022. Company founded

CryoVox Technologies

Brief Description

Crovox Technologies is developing new tools for the mass manufacturing of 3D cell cultures.

Inventors

Boris Rubinsky, Michal Adamkievicz, Ze'ev Shaked

Timeline 2024. Company founded

Singulex, Inc.

Brief Description

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The...

QSX Bio

Brief Description

Developing medical therapeutics and vaccines through biosynthesis of natural compounds in plants.

Inventors

Jay Keasling, Yuzhong Liu, Henrik Scheller, Xiaoyue Chen, Samantha Aiko Crowe, James Reed, Laetitia Martin, Graham Arthur Hudson, Fei Gan

Company Founders

Yuzhong Liu

Timeline 2025. Company founded

ReRx Therapeutics

Brief Description

ReRx is developing novel oral small molecule therapeutics to treat patients with severe metabolic diseases including obesity, metabolic syndrome, diabetes, and liver diseases. The company's therapeutics target metabolic pathways involved in regulating energy homeostasis and improve treatment outcomes compared to similar pharmacological agents.

Obesity and its associated metabolic diseases remain leading causes of preventable illness and mortality worldwide. Current front-line treatments, notably injectable incretin analogs that suppress appetite and reduce food...

Resvita Biosciences

Brief Description

Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.

Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced...

AsparaGlue

Brief Description

AsparaGlue has developed a superglue-like medical adhesive for external wound closure and internal tissue adhesion. The proprietary technology is the world’s only biocompatible and biodegradable medical superglue.

Inventors

Philip Messersmith, Subhajit Pal, Ji Soo Shin, Kelsey Gray DeFrates

Company Founders

UC Berkeley Professor Phillip Messersmith (Ph.D., Professor of Bioengineering and Materials Science & Engineering) and Subhajit Pal (postdoc, 2022-present, Messersmith Lab)

Timeline 2023. Company founded; joins Berkeley Skydeck...

BreezeBio

Brief Description

BreezeBio develops innovative therapies through targeted delivery of genetic medicines. The company's founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe and effective medicines for genetic diseases.

The company's proprietary Polymer nanoparticle can deliver CRISPR protein and gRNA. CRISPR in a protein form has many advantages, delivery has been a challenge limiting its application. To deliver CRISPR protein, encapsulation of CRISPR ribonucleoprotein...

Inapill

Brief Description

Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.

The company was co-founded by Greg Timblin and Josh Farahzad. CEO Timblin earned his Ph.D. in Molecular & Cell Biology from UC Berkeley in 2014, in the labs of Professors Mark Schlissel and Robert Tjian. He also served as a postdoctoral fellow in Professor Kaoru Saijo’s lab at UC Berkeley, and then in Professor Val Weaver’s lab at UCSF.

Inventors

Kaoru Saijo, Greg Timblin...

Stylus Medicine

Brief Description

Stylus Medicine has created a new gene editing technology based on viral proteins called recombinases. These proteins naturally insert large swaths of DNA into bacterial genomes, but Stylus used machine learning to design recombinases that target specific regions of the human genome. The method is based on the pioneering work of Patrick Hsu, UC Berkeley assistant professor of bioengineering and co-founder and a core investigator of the Arc Institute. The company is on a mission to develop next-generation therapies for disease through genome engineering and chromatin...